School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Novavax Inc NVAX

Healthcare · Biotechnology

$12.75last close 2026-10-09 · market cap $2.10B · delayed data

Trailing returns

1M+29.44%
3M+35.64%
6M+49.30%
1Y+48.43%
5Y-92.23%

Basis: Adjusted daily closes.

What it does

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.

Open NVAX in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies